Pharmacokinetic-pharmacodynamic optimization of triazole antifungal therapy

Current Opinion in Infectious Diseases

Volumn 24, Issue SUPPL. 2, 2011, Pages

  Lewis, Russell E ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

Pharmacodynamic; Pharmacokinetic; Posaconazole; Triazoles; Voriconazole

Indexed keywords

CYTOCHROME P450; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG INDICATION; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG STRUCTURE; ENZYME INHIBITION; GLUCURONIDATION; HUMAN; LIPID DIET; LIVER METABOLISM; MYCOSIS; NONHUMAN; NUTRITIONAL STATUS; PHARMACODYNAMICS; REVIEW; STOMACH PH; TREATMENT OUTCOME;

EID: 79959835114     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/01.qco.0000399603.91138.e7     Document Type: Review

References (104)

1. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010; 36:1-53.
2. Mohr J, Johnson M, Cooper T, et al. Current options in antifungal pharmacotherapy. Pharmacotherapy 2008; 28:614-645. (Pubitemid 351620030)
3. Groll AH, Gea-Banacloche JC, Glasmacher A, et al. Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am 2003; 17:159-191; ix.
4. Denning DW, Hope WW. Therapy for fungal diseases: opportunities and priorities. Trends Microbiol 2010; 18:195-204.
5. Dodds Ashley ES, Lewis R, Lewis JS, et al. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006; 43:S28-S39. (Pubitemid 44078894)
6. Lewis RE, Wiederhold NP, Klepser ME. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp. Antimicrob Agents Chemother 2005; 49:945-951. (Pubitemid 40327708)
7. Mellinghoff IK, Winston DJ, Mukwaya G, Schiller GJ. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis 2002; 34:1648-1650. (Pubitemid 34615452)
8. Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 2008; 52:1743-1750. (Pubitemid 351614668)
9. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: Review of the literature. Mycopathologia 2001; 150:101-115. (Pubitemid 32623880)
10. Warrilow AG, Martel CM, Parker JE, et al. Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51). Antimicrob Agents Chemother 2010; 54:4235-4245.
11. Lipp HP. Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: An overview. Br J Clin Pharmacol 2010; 70:471-480.
12. Li Y, Theuretzbacher U, Clancy CJ, et al. Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet 2010; 49:379-396.
13. Purkins L, Wood N, Kleinermans D, et al. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol 2003; 56 (Suppl 1):17-23. (Pubitemid 37491729)
14. Purkins L, Wood N, Kleinermans D, Nichols D. Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol 2003; 56 (Suppl 1):51-55. (Pubitemid 37491734)
15. Zimmermann T, Yeates RA, Laufen H, et al. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol 1994; 46:147-150. (Pubitemid 24101333)
16. Zimmermann T, Yeates RA, Riedel KD, et al. The influence of gastric pH on the pharmacokinetics of fluconazole: the effect of omeprazole. Int J Clin Pharmacol Ther 1994; 32:491-496. (Pubitemid 24277060)
17. Vrend [package insert]. New York, NY: Pfizer Inc.; 2010.
18. Michael C, Bierbach U, Frenzel K, et al. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. Antimicrob Agents Chemother 2010; 54:3225-3232.
19. Neely M, Rushing T, Kovacs A, et al. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 2010; 50:27-36.
20. Sporanox oral solution [package insert]. Raritan, NJ: Orth Biotech Products, L.P.; 2003.
21. Van De Velde VJ, Van Peer AP, Heykants JJ, et al. Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Pharmacotherapy 1996; 16:424-428.
22. Sporanox capsules [package insert]. Raritan, New Jersey: PriCara; 2009.
23. Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993; 37:778-784. (Pubitemid 23096878)
24. Van Peer A, Woestenborghs R, Heykants J, et al. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol 1989; 36:423-426. (Pubitemid 19140050)
25. Ezzet F, Wexler D, Courtney R, et al. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005; 44:211-220. (Pubitemid 40188942)
26. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006; 50:658-666. (Pubitemid 43190980)
27. Noxafil [package insert]. Kenilworth, New Jersey: Schering-Plough; 2009.
28. Courtney R, Radwanski E, Lim J, Laughlin M. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004; 48:804-808. (Pubitemid 38280328)
29. Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004; 57:218-222. (Pubitemid 38223535)
30. Krishna G, Moton A, Ma L, et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009; 53:958-966.
31. Sansone-Parsons A, Krishna G, Calzetta A, et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 2006; 50:1881-1883.
32. Diflucan [package insert]. New York, New York: Pfizer Inc.; 2010.
33. Dodds-Ashley E. Management of drug and food interactions with azole antifungal agents in transplant recipients. Pharmacotherapy 2010; 30:842-854.
34. Arndt CA, Walsh TJ, McCully CL, et al. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J Infect Dis 1988; 157:178-180. (Pubitemid 18037468)
35. Foulds G, Brennan DR, Wajszczuk C, et al. Fluconazole penetration into cerebrospinal fluid in humans. J Clin Pharmacol 1988; 28:363-366. (Pubitemid 19013387)
36. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003; 37:728-732. (Pubitemid 37100817)
37. Perfect JR, Cox GM, Dodge RK, Schell WA. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother 1996; 40:1910-1913. (Pubitemid 26277814)
38. Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005; 56:745-755. (Pubitemid 41487778)
39. Barchiesi F, Schimizzi AM, Caselli F, et al. Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob Agents Chemother 2000; 44:2435-2441. (Pubitemid 30650892)
40. Barchiesi F, Spreghini E, Schimizzi AM, et al. Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection. Antimicrob Agents Chemother 2004; 48:3312-3316. (Pubitemid 39129324)
41. Esposito V, Viglietti R, Gargiulo M, et al. Successful treatment of Cryptococcal meningitis with a combination of liposomal amphotericin B, flucytosine and posaconazole: two case reports. In Vivo 2009; 23:465-468.
42. Heykants J, Van Peer A, Van de Velde V, et al. The clinical pharmacokinetics of itraconazole: An overview. Mycoses 1989; 32 (Suppl 1):67-87.
43. Nivoix Y, Ubeaud-Sequier G, Engel P, et al. Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care. Curr Drug Metab 2009; 10:395-409.
44. Hafner V, Czock D, Burhenne J, et al. Pharmacokinetics of sulfobutyletherbeta- cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. Antimicrob Agents Chemother 2010; 54:2596-2602.
45. Keating GM. Posaconazole. Drugs 2005; 65:1553-1567; discussion 1568-1559.
46. Krieter P, Flannery B, Musick T, et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004; 48:3543-3551. (Pubitemid 39129357)
47. Wexler D, Courtney R, Richards W, et al. Effect of posaconazole on cytochrome P450 enzymes: A randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004; 21:645-653. (Pubitemid 38447146)
48. Picard N, Ratanasavanh D, Premaud A, et al. Identification of the UDPglucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 2005; 33:139-146. (Pubitemid 40023525)
49. Ghosal A, Hapangama N, Yuan Y, et al. Identification of human UDPglucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos 2004; 32:267-271. (Pubitemid 38176945)
50. Andes D, Marchillo K, Conklin R, et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother 2004; 48:137-142. (Pubitemid 38040189)
51. Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47:3165-3169. (Pubitemid 37229574)
52. Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47:1193-1199. (Pubitemid 36368574)
53. Andes D, van Ogtrop M. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 1999; 43:2116-2120. (Pubitemid 29421186)
54. Louie A, Drusano GL, Banerjee P, et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother 1998; 42:1105-1109. (Pubitemid 28227905)
55. Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am 2006; 20:679-697. (Pubitemid 44375115)
56. Andes D. Clinical pharmacodynamics of antifungals. Infect Dis Clin North Am 2003; 17:635-649. (Pubitemid 38029157)
57. Andes D. Clinical utility of antifungal pharmacokinetics and pharmacodynamics. Curr Opin Infect Dis 2004; 17:533-540. (Pubitemid 39627514)
58. Mavridou E, Bruggemann RJ, Melchers WJ, et al. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother 2010; 54:4758-4764.
59. Mavridou E, Bruggemann RJ, Melchers WJ, et al. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother 2010; 54:860-865.
60. Rex JH, Pfaller MA, Walsh TJ, et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001; 14:643-658; table of contents. (Pubitemid 32979625)
61. Baddley JW, Patel M, Bhavnani SM, et al. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother 2008; 52:3022-3028.
62. Clancy CJ, Yu VL, Morris AJ, et al. Fluconazole MIC and the fluconazole dose/ MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother 2005; 49:3171-3177. (Pubitemid 41060556)
63. Labelle AJ, Micek ST, Roubinian N, Kollef MH. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008; 36:2967-2972.
64. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious diseases society of America. Clin Infect Dis 2009; 48:503-535.
65. Garey KW, Pai MP, Suda KJ, et al. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf 2007; 16:919-927. (Pubitemid 47322590)
66. Nguyen DM, El-Serag HB. The epidemiology of obesity. Gastroenterol Clin North Am 2010; 39:1-7.
67. Csajka C, Decosterd LA, Buclin T, et al. Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients. Eur J Clin Pharmacol 2001; 57:723-727. (Pubitemid 34031265)
68. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009; 53:24-34.
69. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41:913-958. (Pubitemid 35168437)
70. Scholz I, Oberwittler H, Riedel KD, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol 2009; 68:906-915.
71. Wang G, Lei HP, Li Z, et al. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol 2009; 65:281-285.
72. Weiss J, Ten Hoevel MM, Burhenne J, et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol 2009; 49:196-204.
73. Matsumoto K, Ikawa K, Abematsu K, et al. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents 2009; 34: 91-94.
74. Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 109:1532-1535. (Pubitemid 46595688)
75. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201-211. (Pubitemid 351269158)
76. Pascual A, Nieth V, Calandra T, et al. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob Agents Chemother 2007; 51:137-143. (Pubitemid 46047698)
77. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50:1570-1572.
78. Imhof A, Schaer DJ, Schanz U, Schwarz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 2006; 136:739-742. (Pubitemid 46032197)
79. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34:563-571. (Pubitemid 34165316)
80. Tan K, Brayshaw N, Tomaszewski K, et al. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006; 46:235-243. (Pubitemid 43146453)
81. Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005; 35:509-513. (Pubitemid 40403355)
82. Pfaller MA, Diekema DJ, Rex JH, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: Analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006; 44:819-826.
83. Eiden C, Peyriere H, Tichit R, et al. Inherited long QT syndrome revealed by antifungals drug-drug interaction. J Clin Pharm Ther 2007; 32:321-324. (Pubitemid 46699512)
84. Esch JJ, Kantoch MJ. Torsades de Pointes ventricular tachycardia in a pediatric patient treated with fluconazole. Pediatr Cardiol 2008; 29:210-213.
85. Justo D, Zeltser D. Torsade de pointes induced by systemic antifungal agents: lessons from a retrospective analysis of published case reports. Mycoses 2006; 49:463-470. (Pubitemid 44511096)
86. Owens RC Jr, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis 2006; 43:1603-1611. (Pubitemid 44910994)
87. Pham CP, de Feiter PW, van der Kuy PH, van Mook WN. Long QTc interval and torsade de pointes caused by fluconazole. Ann Pharmacother 2006; 40:1456-1461. (Pubitemid 44204980)
88. Prosser JM, Mills A, Rhim ES, Perrone J. Torsade de pointes caused by polypharmacy and substance abuse in a patient with human immunodeficiency virus. Int J Emerg Med 2008; 1:217-220.
89. Tatetsu H, Asou N, Nakamura M, et al. Torsades de pointes upon fluconazole administration in a patient with acute myeloblastic leukemia. Am J Hematol 2006; 81:366-369.
90. Mulanovich V, Lewis RE, Raad II, Kontoyiannis DP. Random plasma concentrations of voriconazole decline over time. J Infect 2007; 55: e129-e130. (Pubitemid 47611512)
91. Abel S, Allan R, Gandelman K, et al. Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies. Clin Drug Investig 2008; 28:409-420. (Pubitemid 351821478)
92. Gubbins PO, Krishna G, Sansone-Parsons A, et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother 2006; 50:1993-1999. (Pubitemid 43807517)
93. Kohl V, Muller C, Cornely A, et al. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother 2010; 54:207-212.
94. Krishna G, Parsons A, Kantesaria B, Mant T. Evaluation of the pharmacokinetics of posaconazole and rifabutin following coadministration to healthy men. Curr Med Res Opin 2007; 23:545-552. (Pubitemid 46456902)
95. Jain R, Pottinger P. The effect of gastric acid on the absorption of posacaonzole [letter]. Clin Infect Dis 2008; 46:1627. (Pubitemid 351706748)
96. Krishna G, Ma L, Vickery D, et al. Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 2009; 53:4749-4752.
97. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335-347. (Pubitemid 46148776)
98. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348-359. (Pubitemid 46148777)
99. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin Infect Dis 2007; 44: 2-12. (Pubitemid 44968977)
100. Jang SH, Colangelo PM, Gobburu JV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 2010; 88:115-119.
101. Krishna G, Martinho M, Chandrasekar P, et al. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007; 27:1627-1636. (Pubitemid 350234311)
102. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother 2001; 45:857-869. (Pubitemid 32182037)
103. Lewis RE. Antifungal drug monitoring. Curr Fungal Infect Rep 2010; 4:158-167.
104. Schumacher GE, editor. Introduction to therapeutic drug monitoring. Norwalk, CT: Appleton and Lange; 1995.